Sorrento Therapeutics Inc. / Concortis Biosystems Corp.

Oncology — Antibody-Drug Conjugate (ADC) Platform

Disease Overview

Antibody-drug conjugates link a tumor-targeting monoclonal antibody to a cytotoxic payload via a chemical linker, delivering chemotherapy selectively to cancer cells. First-generation ADCs (Mylotarg, Adcetris, Kadcyla) used random lysine or cysteine conjugation, producing heterogeneous drug-antibody ratio (DAR) mixtures with sub-optimal pharmacokinetics, off-target toxicity, and narrow therapeutic windows.

Competitive Landscape

By late 2013, the ADC landscape was anchored by two FDA-approved products — Seattle Genetics' Adcetris (brentuximab vedotin, 2011, Hodgkin lymphoma / sALCL) and Roche/Genentech's Kadcyla (T-DM1, Feb 2013, HER2+ metastatic breast cancer). Pfizer's Mylotarg had been withdrawn (2010) and ImmunoGen, Seattle Genetics (linker/payload licensing), Mersana (Fleximer), Pierre Fabre, and Synthon were the principal platform players. Site-specific conjugation was the next-generation battleground: Ambrx (non-natural amino acid), Sutro Biopharma (cell-free, XpressCF), Catalent/Redwood (SMARTag transglutaminase), and Concortis (C-Lock disulfide-rebridging / K-Lock lysine site-specific) competed to deliver homogeneous DAR products. Sorrento's $11.3M stock-only acquisition (1,331,978 shares; closing 19 Dec 2013; https://www.prnewswire.com/news-releases/sorrento-therapeutics-completes-acquisition-of-concortis-biosystems-236645171.html) gave it full-stack ADC ownership — antibodies (G-MAB library), site-specific chemistries (C-Lock/K-Lock), proprietary toxins, and linkers — under the same roof, a configuration CEO Henry Ji argued 'very few companies' had. Strategically, the deal reframed Sorrento from a pure antibody-discovery shop into an ADC platform play and set up planned 2015 IND filings for an anti-PD-L1 mAb and a VEGFR2-targeting ADC. Concortis CSO David Miao was named Sorrento CTO.